Clinical trial
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid…
NCT00012376 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00012376 |
|---|---|
| Title | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer |
| Official title | Dose Finding Study of Bryostatin-1 and GM-CSF in Refractory Myeloid Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13 and 13 more |
| Intervention type | Biological, Drug, Other |
| Interventions | bryostatin 1, sargramostim, laboratory biomarker analysis, pharmacological study |
| Enrollment | 35 |
| Start date | Mar 1, 2001 |
| Primary completion | Jan 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: